Delcath Systems, Inc. (NASDAQ: DCTH) Stock Competitors & Peer Comparison
See DCTH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DCTH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DCTH | $15.96 | -2.68% | 551M | 1596.00 | $0.01 | N/A |
| ABT | $103.49 | -0.23% | 179.1B | 19.87 | $5.21 | +2.40% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $89.30 | -1.62% | 114.3B | 16.15 | $5.53 | +3.21% |
| SYK | $273.40 | -0.61% | 104.8B | 20.42 | $13.39 | +1.28% |
| BSX | $44.62 | -0.67% | 66.4B | 14.40 | $3.10 | N/A |
| EW | $86.82 | -2.21% | 50B | 32.15 | $2.70 | N/A |
| DXCM | $87.73 | -2.01% | 33.1B | 34.40 | $2.55 | N/A |
| GEHC | $66.09 | -0.27% | 29.9B | 14.49 | $4.56 | +0.21% |
| PHG | $24.45 | -2.08% | 23.9B | 13.97 | $1.75 | +4.04% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
DCTH vs ABT Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ABT has a market cap of 179.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ABT trades at $103.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ABT's P/E ratio is 19.87. In terms of profitability, DCTH's ROE is +0.00%, compared to ABT's ROE of +0.11%. Regarding short-term risk, DCTH is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
DCTH vs BSX-PA Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, DCTH's ROE is +0.00%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, DCTH is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
DCTH vs MDT Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, MDT has a market cap of 114.3B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while MDT trades at $89.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas MDT's P/E ratio is 16.15. In terms of profitability, DCTH's ROE is +0.00%, compared to MDT's ROE of +0.11%. Regarding short-term risk, DCTH is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
DCTH vs SYK Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SYK has a market cap of 104.8B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SYK trades at $273.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SYK's P/E ratio is 20.42. In terms of profitability, DCTH's ROE is +0.00%, compared to SYK's ROE of +0.16%. Regarding short-term risk, DCTH is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
DCTH vs BSX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BSX has a market cap of 66.4B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BSX trades at $44.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BSX's P/E ratio is 14.40. In terms of profitability, DCTH's ROE is +0.00%, compared to BSX's ROE of +0.15%. Regarding short-term risk, DCTH is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
DCTH vs EW Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, EW has a market cap of 50B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while EW trades at $86.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas EW's P/E ratio is 32.15. In terms of profitability, DCTH's ROE is +0.00%, compared to EW's ROE of +0.10%. Regarding short-term risk, DCTH is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
DCTH vs DXCM Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, DXCM has a market cap of 33.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while DXCM trades at $87.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas DXCM's P/E ratio is 34.40. In terms of profitability, DCTH's ROE is +0.00%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, DCTH is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
DCTH vs GEHC Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, GEHC has a market cap of 29.9B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while GEHC trades at $66.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas GEHC's P/E ratio is 14.49. In terms of profitability, DCTH's ROE is +0.00%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, DCTH is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
DCTH vs PHG Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, PHG has a market cap of 23.9B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while PHG trades at $24.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas PHG's P/E ratio is 13.97. In terms of profitability, DCTH's ROE is +0.00%, compared to PHG's ROE of +0.10%. Regarding short-term risk, DCTH is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
DCTH vs ZBH Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ZBH trades at $90.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ZBH's P/E ratio is 10.72. In terms of profitability, DCTH's ROE is +0.00%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, DCTH is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
DCTH vs ABMD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ABMD's P/E ratio is 65.36. In terms of profitability, DCTH's ROE is +0.00%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, DCTH is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
DCTH vs PEN Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while PEN trades at $319.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas PEN's P/E ratio is 83.37. In terms of profitability, DCTH's ROE is +0.00%, compared to PEN's ROE of +0.11%. Regarding short-term risk, DCTH is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
DCTH vs SWAV Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SWAV's P/E ratio is 78.76. In terms of profitability, DCTH's ROE is +0.00%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, DCTH is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
DCTH vs SNN Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SNN trades at $26.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SNN's P/E ratio is 18.10. In terms of profitability, DCTH's ROE is +0.00%, compared to SNN's ROE of +0.12%. Regarding short-term risk, DCTH is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
DCTH vs ALGN Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ALGN has a market cap of 10.6B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ALGN trades at $148.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ALGN's P/E ratio is 13.51. In terms of profitability, DCTH's ROE is +0.00%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, DCTH is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
DCTH vs BIO-B Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BIO-B has a market cap of 10.3B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BIO-B trades at $374.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BIO-B's P/E ratio is -65.99. In terms of profitability, DCTH's ROE is +0.00%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, DCTH is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
DCTH vs BIO Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BIO trades at $378.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BIO's P/E ratio is 40.83. In terms of profitability, DCTH's ROE is +0.00%, compared to BIO's ROE of +0.03%. Regarding short-term risk, DCTH is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
DCTH vs GMED Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, GMED has a market cap of 10B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while GMED trades at $73.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas GMED's P/E ratio is 16.66. In terms of profitability, DCTH's ROE is +0.00%, compared to GMED's ROE of +0.12%. Regarding short-term risk, DCTH is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check GMED's competition here
Insulet Corp. (NASDAQ: PODD)
DCTH vs PODD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, PODD has a market cap of 9.5B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while PODD trades at $136.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas PODD's P/E ratio is 23.25. In terms of profitability, DCTH's ROE is +0.00%, compared to PODD's ROE of +0.27%. Regarding short-term risk, DCTH is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
DCTH vs MASI Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas MASI's P/E ratio is 44.43. In terms of profitability, DCTH's ROE is +0.00%, compared to MASI's ROE of +0.09%. Regarding short-term risk, DCTH is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
DCTH vs BRKR Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BRKR trades at $59.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BRKR's P/E ratio is 29.98. In terms of profitability, DCTH's ROE is +0.00%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, DCTH is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check BRKR's competition here
Glaukos Corporation (NYSE: GKOS)
DCTH vs GKOS Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, GKOS has a market cap of 9.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while GKOS trades at $153.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas GKOS's P/E ratio is -178.48. In terms of profitability, DCTH's ROE is +0.00%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, DCTH is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKRP)
DCTH vs BRKRP Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BRKRP trades at $439.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BRKRP's P/E ratio is 238.95. In terms of profitability, DCTH's ROE is +0.00%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, DCTH is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
DCTH vs HAE Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while HAE trades at $106.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas HAE's P/E ratio is 21.32. In terms of profitability, DCTH's ROE is +0.00%, compared to HAE's ROE of +0.11%. Regarding short-term risk, DCTH is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
DCTH vs NARI Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas NARI's P/E ratio is -59.24. In terms of profitability, DCTH's ROE is +0.00%, compared to NARI's ROE of -0.00%. Regarding short-term risk, DCTH is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
DCTH vs ITGR Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ITGR trades at $126.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ITGR's P/E ratio is 19.89. In terms of profitability, DCTH's ROE is +0.00%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, DCTH is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
DCTH vs LIVN Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while LIVN trades at $77.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas LIVN's P/E ratio is 18.33. In terms of profitability, DCTH's ROE is +0.00%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, DCTH is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
DCTH vs IRTC Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while IRTC trades at $111.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas IRTC's P/E ratio is -259.88. In terms of profitability, DCTH's ROE is +0.00%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, DCTH is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
DCTH vs AXNX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas AXNX's P/E ratio is -709.80. In terms of profitability, DCTH's ROE is +0.00%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, DCTH is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
DCTH vs TMDX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while TMDX trades at $87.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas TMDX's P/E ratio is 44.16. In terms of profitability, DCTH's ROE is +0.00%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, DCTH is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
DCTH vs NEOG Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while NEOG trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas NEOG's P/E ratio is 48.46. In terms of profitability, DCTH's ROE is +0.00%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, DCTH is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check NEOG's competition here
Butterfly Network, Inc. (NYSE: BFLY)
DCTH vs BFLY Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BFLY trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BFLY's P/E ratio is -38.31. In terms of profitability, DCTH's ROE is +0.00%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, DCTH is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check BFLY's competition here
AxoGen, Inc. (NASDAQ: AXGN)
DCTH vs AXGN Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while AXGN trades at $43.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas AXGN's P/E ratio is 114.00. In terms of profitability, DCTH's ROE is +0.00%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, DCTH is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
DCTH vs UFPT Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while UFPT trades at $287.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas UFPT's P/E ratio is 29.35. In terms of profitability, DCTH's ROE is +0.00%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, DCTH is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
DCTH vs NUVA Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas NUVA's P/E ratio is 75.00. In terms of profitability, DCTH's ROE is +0.00%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, DCTH is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
DCTH vs INSP Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while INSP trades at $69.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas INSP's P/E ratio is 30.41. In terms of profitability, DCTH's ROE is +0.00%, compared to INSP's ROE of +0.18%. Regarding short-term risk, DCTH is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
DCTH vs ESTA Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ESTA trades at $67.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ESTA's P/E ratio is -53.78. In terms of profitability, DCTH's ROE is +0.00%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, DCTH is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
DCTH vs NVCR Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while NVCR trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas NVCR's P/E ratio is -12.50. In terms of profitability, DCTH's ROE is +0.00%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, DCTH is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
DCTH vs ATEC Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ATEC trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ATEC's P/E ratio is -167.17. In terms of profitability, DCTH's ROE is +0.00%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, DCTH is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
DCTH vs CNMD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while CNMD trades at $45.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas CNMD's P/E ratio is 10.07. In terms of profitability, DCTH's ROE is +0.00%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, DCTH is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
DCTH vs HSKA Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas HSKA's P/E ratio is -62.49. In terms of profitability, DCTH's ROE is +0.00%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, DCTH is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
DCTH vs IART Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while IART trades at $15.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas IART's P/E ratio is 6.58. In terms of profitability, DCTH's ROE is +0.00%, compared to IART's ROE of -0.01%. Regarding short-term risk, DCTH is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
DCTH vs AVNS Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas AVNS's P/E ratio is 27.77. In terms of profitability, DCTH's ROE is +0.00%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, DCTH is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check AVNS's competition here
Artivion, Inc. (NYSE: AORT)
DCTH vs AORT Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while AORT trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas AORT's P/E ratio is 39.20. In terms of profitability, DCTH's ROE is +0.00%, compared to AORT's ROE of -0.01%. Regarding short-term risk, DCTH is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check AORT's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
DCTH vs TNDM Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while TNDM trades at $16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas TNDM's P/E ratio is -17.61. In terms of profitability, DCTH's ROE is +0.00%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, DCTH is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
DCTH vs SILK Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SILK's P/E ratio is -18.96. In terms of profitability, DCTH's ROE is +0.00%, compared to SILK's ROE of -0.35%. Regarding short-term risk, DCTH is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
DCTH vs IRMD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while IRMD trades at $86.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas IRMD's P/E ratio is 43.39. In terms of profitability, DCTH's ROE is +0.00%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, DCTH is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
DCTH vs FNA Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas FNA's P/E ratio is -19.83. In terms of profitability, DCTH's ROE is +0.00%, compared to FNA's ROE of -0.35%. Regarding short-term risk, DCTH is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
DCTH vs ENOV Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ENOV trades at $18.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ENOV's P/E ratio is 5.22. In terms of profitability, DCTH's ROE is +0.00%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, DCTH is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ENOV's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
DCTH vs PRCT Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while PRCT trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas PRCT's P/E ratio is -9.32. In terms of profitability, DCTH's ROE is +0.00%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, DCTH is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check PRCT's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
DCTH vs BBNX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BBNX has a market cap of 998.3M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BBNX trades at $22.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BBNX's P/E ratio is -13.45. In terms of profitability, DCTH's ROE is +0.00%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, DCTH is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check BBNX's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
DCTH vs LMRI Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, LMRI has a market cap of 974.3M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while LMRI trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas LMRI's P/E ratio is -19.73. In terms of profitability, DCTH's ROE is +0.00%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, DCTH is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
DCTH vs BVS Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BVS has a market cap of 922.1M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BVS trades at $13.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BVS's P/E ratio is 17.91. In terms of profitability, DCTH's ROE is +0.00%, compared to BVS's ROE of +0.28%. Regarding short-term risk, DCTH is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
DCTH vs CBLL Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, CBLL has a market cap of 896.2M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while CBLL trades at $23.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas CBLL's P/E ratio is -13.42. In terms of profitability, DCTH's ROE is +0.00%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, DCTH is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check CBLL's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
DCTH vs CSII Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas CSII's P/E ratio is -20.83. In terms of profitability, DCTH's ROE is +0.00%, compared to CSII's ROE of -0.14%. Regarding short-term risk, DCTH is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
DCTH vs SIBN Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SIBN has a market cap of 824.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SIBN trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SIBN's P/E ratio is -54.71. In terms of profitability, DCTH's ROE is +0.00%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, DCTH is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
DCTH vs INMD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, INMD has a market cap of 815.7M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while INMD trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas INMD's P/E ratio is 9.85. In terms of profitability, DCTH's ROE is +0.00%, compared to INMD's ROE of +0.12%. Regarding short-term risk, DCTH is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
DCTH vs VREX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while VREX trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas VREX's P/E ratio is 19.42. In terms of profitability, DCTH's ROE is +0.00%, compared to VREX's ROE of +0.05%. Regarding short-term risk, DCTH is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
DCTH vs AHCO Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, AHCO has a market cap of 775.5M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while AHCO trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas AHCO's P/E ratio is 11.63. In terms of profitability, DCTH's ROE is +0.00%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, DCTH is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
DCTH vs AVR Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, AVR has a market cap of 740.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while AVR trades at $7.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas AVR's P/E ratio is -3.93. In terms of profitability, DCTH's ROE is +0.00%, compared to AVR's ROE of -0.78%. Regarding short-term risk, DCTH is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check AVR's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
DCTH vs CTKB Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, CTKB has a market cap of 733.5M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while CTKB trades at $5.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas CTKB's P/E ratio is -30.09. In terms of profitability, DCTH's ROE is +0.00%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, DCTH is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check CTKB's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
DCTH vs SSII Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SSII has a market cap of 622.4M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SSII trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SSII's P/E ratio is -51.83. In terms of profitability, DCTH's ROE is +0.00%, compared to SSII's ROE of -0.27%. Regarding short-term risk, DCTH is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
DCTH vs SRDX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SRDX's P/E ratio is -34.66. In terms of profitability, DCTH's ROE is +0.00%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, DCTH is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SRDX's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
DCTH vs APEN Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas APEN's P/E ratio is -9.43. In terms of profitability, DCTH's ROE is +0.00%, compared to APEN's ROE of -0.85%. Regarding short-term risk, DCTH is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
DCTH vs KIDS Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, KIDS has a market cap of 573.5M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while KIDS trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas KIDS's P/E ratio is -18.92. In terms of profitability, DCTH's ROE is +0.00%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, DCTH is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check KIDS's competition here
ZimVie Inc. (NASDAQ: ZIMV)
DCTH vs ZIMV Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, DCTH's ROE is +0.00%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, DCTH is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
DCTH vs CERS Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, CERS has a market cap of 524M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while CERS trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas CERS's P/E ratio is -86.38. In terms of profitability, DCTH's ROE is +0.00%, compared to CERS's ROE of -0.10%. Regarding short-term risk, DCTH is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
DCTH vs TCMD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, TCMD has a market cap of 505.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while TCMD trades at $22.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas TCMD's P/E ratio is 20.77. In terms of profitability, DCTH's ROE is +0.00%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, DCTH is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
DCTH vs NPCE Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, NPCE has a market cap of 484.5M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while NPCE trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas NPCE's P/E ratio is -24.93. In terms of profitability, DCTH's ROE is +0.00%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, DCTH is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check NPCE's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
DCTH vs SGHT Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SGHT has a market cap of 462.5M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SGHT trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SGHT's P/E ratio is -15.18. In terms of profitability, DCTH's ROE is +0.00%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, DCTH is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SGHT's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
DCTH vs CLPT Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, CLPT has a market cap of 448.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while CLPT trades at $14.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas CLPT's P/E ratio is -12.69. In terms of profitability, DCTH's ROE is +0.00%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, DCTH is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check CLPT's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
DCTH vs PACB Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, PACB has a market cap of 437.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while PACB trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas PACB's P/E ratio is -3.44. In terms of profitability, DCTH's ROE is +0.00%, compared to PACB's ROE of -49.62%. Regarding short-term risk, DCTH is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check PACB's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
DCTH vs SENS Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SENS has a market cap of 416.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SENS trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SENS's P/E ratio is -4.47. In terms of profitability, DCTH's ROE is +0.00%, compared to SENS's ROE of -1.66%. Regarding short-term risk, DCTH is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
DCTH vs OFIX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, OFIX has a market cap of 371.1M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while OFIX trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas OFIX's P/E ratio is -5.98. In terms of profitability, DCTH's ROE is +0.00%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, DCTH is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check OFIX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
DCTH vs SMLR Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas SMLR's P/E ratio is 3.92. In terms of profitability, DCTH's ROE is +0.00%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, DCTH is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check SMLR's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
DCTH vs TLSI Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, TLSI has a market cap of 307.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while TLSI trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas TLSI's P/E ratio is -2.98. In terms of profitability, DCTH's ROE is +0.00%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, DCTH is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
DCTH vs CV Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, CV has a market cap of 302.3M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while CV trades at $6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas CV's P/E ratio is -9.60. In terms of profitability, DCTH's ROE is +0.00%, compared to CV's ROE of -1.78%. Regarding short-term risk, DCTH is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check CV's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
DCTH vs CATX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, CATX has a market cap of 298.4M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while CATX trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas CATX's P/E ratio is -1.97. In terms of profitability, DCTH's ROE is +0.00%, compared to CATX's ROE of -0.42%. Regarding short-term risk, DCTH is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check CATX's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
DCTH vs TMCI Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, TMCI has a market cap of 292.6M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while TMCI trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas TMCI's P/E ratio is -4.80. In terms of profitability, DCTH's ROE is +0.00%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, DCTH is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check TMCI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
DCTH vs RCEL Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, RCEL has a market cap of 272M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while RCEL trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas RCEL's P/E ratio is -7.60. In terms of profitability, DCTH's ROE is +0.00%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, DCTH is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check RCEL's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
DCTH vs INFU Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, INFU has a market cap of 257.5M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while INFU trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas INFU's P/E ratio is 31.12. In terms of profitability, DCTH's ROE is +0.00%, compared to INFU's ROE of +0.15%. Regarding short-term risk, DCTH is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
DCTH vs MGRM Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas MGRM's P/E ratio is -12.00. In terms of profitability, DCTH's ROE is +0.00%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, DCTH is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
DCTH vs ELMD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ELMD has a market cap of 229.8M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ELMD trades at $27.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ELMD's P/E ratio is 21.18. In terms of profitability, DCTH's ROE is +0.00%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, DCTH is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
DCTH vs NVRO Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas NVRO's P/E ratio is -1.91. In terms of profitability, DCTH's ROE is +0.00%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, DCTH is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
DCTH vs PROF Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, PROF has a market cap of 208.4M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while PROF trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas PROF's P/E ratio is -5.85. In terms of profitability, DCTH's ROE is +0.00%, compared to PROF's ROE of -0.56%. Regarding short-term risk, DCTH is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
DCTH vs RXST Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, RXST has a market cap of 200.8M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while RXST trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas RXST's P/E ratio is -4.29. In terms of profitability, DCTH's ROE is +0.00%, compared to RXST's ROE of -0.17%. Regarding short-term risk, DCTH is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check RXST's competition here
Neuronetics, Inc. (NASDAQ: STIM)
DCTH vs STIM Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, STIM has a market cap of 200.4M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while STIM trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas STIM's P/E ratio is -6.55. In terms of profitability, DCTH's ROE is +0.00%, compared to STIM's ROE of -1.51%. Regarding short-term risk, DCTH is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
DCTH vs BSGM Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas BSGM's P/E ratio is -5.81. In terms of profitability, DCTH's ROE is +0.00%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, DCTH is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
DCTH vs MDGS Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas MDGS's P/E ratio is -0.27. In terms of profitability, DCTH's ROE is +0.00%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, DCTH is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check MDGS's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
DCTH vs FOCL Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, FOCL has a market cap of 177.7M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while FOCL trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas FOCL's P/E ratio is -4.58. In terms of profitability, DCTH's ROE is +0.00%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, DCTH is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check FOCL's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
DCTH vs QIPT Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas QIPT's P/E ratio is -15.87. In terms of profitability, DCTH's ROE is +0.00%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, DCTH is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check QIPT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
DCTH vs LUCD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, LUCD has a market cap of 160M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while LUCD trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas LUCD's P/E ratio is -2.27. In terms of profitability, DCTH's ROE is +0.00%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, DCTH is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check LUCD's competition here
Quantum-Si incorporated (NASDAQ: QSI)
DCTH vs QSI Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, QSI has a market cap of 150.1M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while QSI trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas QSI's P/E ratio is -1.65. In terms of profitability, DCTH's ROE is +0.00%, compared to QSI's ROE of -0.47%. Regarding short-term risk, DCTH is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check QSI's competition here
Quanterix Corporation (NASDAQ: QTRX)
DCTH vs QTRX Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, QTRX has a market cap of 148.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while QTRX trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas QTRX's P/E ratio is -1.24. In terms of profitability, DCTH's ROE is +0.00%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, DCTH is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check QTRX's competition here
Inogen, Inc. (NASDAQ: INGN)
DCTH vs INGN Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, INGN has a market cap of 137.8M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while INGN trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas INGN's P/E ratio is -5.59. In terms of profitability, DCTH's ROE is +0.00%, compared to INGN's ROE of -0.13%. Regarding short-term risk, DCTH is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
DCTH vs ICAD Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ICAD's P/E ratio is -20.37. In terms of profitability, DCTH's ROE is +0.00%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, DCTH is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ICAD's competition here
electroCore, Inc. (NASDAQ: ECOR)
DCTH vs ECOR Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ECOR has a market cap of 103M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ECOR trades at $11.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ECOR's P/E ratio is -6.80. In terms of profitability, DCTH's ROE is +0.00%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, DCTH is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check ECOR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
DCTH vs HJLI Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas HJLI's P/E ratio is N/A. In terms of profitability, DCTH's ROE is +0.00%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, DCTH is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for DCTH.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
DCTH vs ASXC Comparison September 2026
Delcath Systems, Inc. (NASDAQ: DCTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCTH stands at 551M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, DCTH is priced at $15.96 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCTH currently has a P/E ratio of 1596.00, whereas ASXC's P/E ratio is -1.12. In terms of profitability, DCTH's ROE is +0.00%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, DCTH is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for DCTH.Check ASXC's competition here